FUCA2

Plasma alpha-L-fucosidase · Q9BTY2 · FUCA2 on Sugi Atlas →

186 patent compounds predicted against FUCA2, 165 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19363645	0.57	2/20
Deoxyfuconojirimycin (SCHEMBL466591)	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL1867289)	1.00	1/20
SCHEMBL2434142	1.00	1/20
SCHEMBL2434219	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL2435560)	1.00	1/20
SCHEMBL2435752	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL2436650)	1.00	1/20
SCHEMBL2438896	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL4378188)	1.00	1/20
SCHEMBL6624061	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL7890925)	1.00	1/20
SCHEMBL9629164	1.00	1/20
SCHEMBL9789719	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL9999893)	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL12581516)	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL13328524)	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL13876082)	1.00	1/20
SCHEMBL13876085	1.00	1/20
Deoxyfuconojirimycin (SCHEMBL13876087)	1.00	1/20

Clinical trials — most relevant to FUCA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease	PHASE4	COMPLETED
High Dose or High Dose Frequency Study of Alglucosidase Alfa	PHASE4	COMPLETED
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen	PHASE4	COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD	PHASE4	RECRUITING
Hemlibra in Mild Hemophilia A	PHASE4	RECRUITING
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease	PHASE3	COMPLETED
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)	PHASE3	COMPLETED
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases	PHASE2/PHASE3	COMPLETED
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease	PHASE3	COMPLETED
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis	PHASE3	WITHDRAWN
Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II	PHASE1/PHASE2	COMPLETED
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease	PHASE2	COMPLETED
Replagal Enzyme Replacement Therapy for Children With Fabry Disease	PHASE2	COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old	PHASE2	COMPLETED
Evaluate the Safety and Exploratory Efficacy of GC1119	PHASE1	COMPLETED
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I	PHASE1	RECRUITING
Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus	PHASE1	COMPLETED
Longitudinal Studies of the Glycoproteinoses	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers	nan	UNKNOWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Early Detection and Follow-Up of Patients With Fabry's Disease	nan	UNKNOWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?	nan	COMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FUCA2 binder may also engage these)

Protein	Name	Similarity
Q5RFI5	—	1.000	Q5RFI5 →
Q6AYS4	—	1.000	Q6AYS4 →
Q99KR8	—	0.994	Q99KR8 →
Q99LJ1	—	0.990	Q99LJ1 →
FUCA1	Tissue alpha-L-fucosidase	0.990	landscape →
P48300	—	0.987	P48300 →
P17164	—	0.984	P17164 →
C3YWU0	—	0.982	C3YWU0 →
Q60HF8	—	0.981	Q60HF8 →
Q2KIM0	—	0.981	Q2KIM0 →
Q8K2I4	—	0.978	Q8K2I4 →
Q9VTJ4	—	0.978	Q9VTJ4 →
Q29444	—	0.976	Q29444 →
P12265	—	0.976	P12265 →
PLOD1	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1	0.976	landscape →
P79403	—	0.974	P79403 →
Q95327	—	0.974	Q95327 →
Q9FNA3	—	0.974	Q9FNA3 →
P20060	—	0.974	P20060 →
Q1L8D2	—	0.973	Q1L8D2 →
Q9MAJ7	—	0.973	Q9MAJ7 →
HEXA	Beta-hexosaminidase subunit alpha	0.972	landscape →
Q9QWR8	—	0.972	Q9QWR8 →
O97524	—	0.971	O97524 →
O77588	—	0.971	O77588 →
Q5R5N6	—	0.971	Q5R5N6 →
P27046	—	0.971	P27046 →
MANBA	Beta-mannosidase	0.971	landscape →
O77695	—	0.970	O77695 →
Q5R9N3	—	0.970	Q5R9N3 →